In short
Clinical trials are studying AUTOLOGOUS DENDRITIC CELLS PULSED WITH ALLOGENEIC TUMOUR CELL LYSATE in people with lung cancer. These studies look at whether the treatment can help keep the cancer from growing after first treatment, and they measure outcomes such as safety and progression-free survival.
Key points
- Clinical trials of AUTOLOGOUS DENDRITIC CELLS PULSED WITH ALLOGENEIC TUMOUR CELL LYSATE in the provided data focused on lung cancer, especially extensive stage small cell lung cancer. The main study was a Phase 2/3 interventional trial in 20 participants who had already received induction treatment. It tested the treatment as maintenance therapy together with atezolizumab. The main outcome was progression-free survival rate at 6 months, meaning how many people were alive without the cancer getting worse. The trial was completed.
Trial overview
The available trial data describe one interventional study, which means the researchers gave a planned treatment and then measured the results. The study investigated AUTOLOGOUS DENDRITIC CELLS PULSED WITH ALLOGENEIC TUMOUR CELL LYSATE in people with lung cancer, with a focus on extensive stage small cell lung cancer.
Who was studied
The trial enrolled people with extensive stage small cell lung cancer, a fast-growing type of lung cancer that has spread widely. These participants had already received induction treatment, meaning first treatment given before the study treatment was started.
Treatment and study setting
The study tested AUTOLOGOUS DENDRITIC CELLS PULSED WITH ALLOGENEIC TUMOUR CELL LYSATE together with atezolizumab as maintenance treatment after induction therapy. The trial record lists intradermal injection for the dendritic cell treatment and intravenous infusion for atezolizumab, which means the medicines were given through the skin and through a vein.
This was a maintenance study, so the goal was not first-line treatment of the cancer, but treatment given after the first treatment phase to help keep the disease under control.
Trial phase and status
The study was a Phase 2/3 trial. Phase 2/3 studies are later-stage trials that look more closely at whether a treatment works and help confirm the findings in a larger setting. The trial status was Completed, and the enrollment was 20 participants.
Main endpoint
The main outcome was progression-free survival (PFS) rate at 6 months. This means the researchers checked how many participants were alive and had no disease progression, or cancer growth, at 6 months, using the RECIST v1.1 method to assess the cancer.
What the results mean for patients
For patients, this trial was designed to see whether AUTOLOGOUS DENDRITIC CELLS PULSED WITH ALLOGENEIC TUMOUR CELL LYSATE could help extend the time before the cancer got worse after initial treatment. The study did not include many people, so it is best seen as an early step in learning how this treatment may perform in this cancer setting.